Unigen expands into Europe, Latin America
Unigen Pharmaceuticals has expanded its sales presence in Europe
and Latin America by signing agency and distribution agreements
with six international corporate partners
ConjuChem hopes to raise C$12m in fund-raising
ConjuChem, a company specialised in improving the formulation of
peptide drugs, has said that it is aiming to raise around C$12
million (€7.6m) in a new private placement round
PowderJect boosts vaccine development and production
PowderJect Pharmaceuticals of the UK has announced plans to invest
£85 million in its facilities in Liverpool. in order to expand its
vaccine development and manufacturing capabilities
Bachem chief looks forward to improved growth
Switzerland's Bachem SA, which specialises in the manufacture and
sale of bulk peptides and related organic chemicals as active
ingredients for the pharmaceutical industry, has announced that it
expects full-year sales growth...
UCB expects flat profits in 2003
Belgian pharmaceuticals and chemicals group UCB has said it expects
its profit in 2003 to be at a level comparable to those of the
previous year, influenced by the unfavourable economic climate, but
especially affected by the fall...
Caliper to buy Zymark in $71m deal
Caliper Technologies has announced its intention to acquire
laboratory automation, liquid handling and robotics specialist
Zymark in a deal valued at around $71 million in cash and stock.
Chiracon joins Berlin's Startup-Partners
Germany's Chiracon, a specialist in novel raw and starting
materials for high-value pharmaceuticals, has joined the circle of
Startup-Partners, the central capital marketing agency for Berlin.
ImClone's Waksal faces sentencing
Sam Waksal, the disgraced former chief executive of US
biotechnology company ImClone Systems, is due for sentencing today
and could receive a jail sentence as well as significant fines.
Protherics says higher profits will follow capacity boost
Protherics has said that it plans to expand its plant in Llandysul,
south Wales, to reduce the manufacturing cost of its products and
boost its profits
Isis and Lilly renegotiate Affinitak production deal
Isis Pharmaceuticals and Eli Lilly say they have reached a mutually
beneficial renegotiation of their manufacturing relationship for
cancer drug Affinitak
Millennium cuts R&D, manufacturing
Millennium Pharmaceuticals has said that it plans to cut around 600
jobs and wind down some of its manufacturing operations as it seeks
to reach profitability by 2006
ICOS gets manufacturing contract from Lilly
ICOS has entered into a biologics manufacturing agreement with Eli
Lilly, in which the Bothell, Washington-based firm will manufacture
two clinical candidates
Patheon Italia signs new deal with Roche
Patheon Italia has extended its manufacturing services agreement
with Roche to continue to supply the Swiss firm with solid, liquid
and sterile products for the European market.
Fall-out hits GSK after AGM 'fat cat' revolt
Two members of GlaxoSmithKline's remuneration committee have
resigned in the wake of the company's defeat by shareholders over
its pay policy.
Xenova to make cancer vaccine for Pharmexa
Xenova of the UK has been awarded a two-year contract by Sweden's
Pharmexa for the manufacture of a vaccine in clinical trials as a
treatment for breast cancer and other tumours.